Elranatamab Elicits Responses in Pretreated Relapsed/Refractory Myeloma

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.

Related Keywords

,Ajayk Nooka ,Eastern Cooperative Oncology Group ,Myeloma International Staging System ,Emory University School Of Medicine ,Emory University School ,Winship Data ,Technology Applications Shared Resource ,Winship Cancer Institute ,Emory University ,Asco Annual Meeting ,Myeloma ,